[go: up one dir, main page]

PE20040945A1 - Preparacion de quinazolinas substituidas - Google Patents

Preparacion de quinazolinas substituidas

Info

Publication number
PE20040945A1
PE20040945A1 PE2004000120A PE2004000120A PE20040945A1 PE 20040945 A1 PE20040945 A1 PE 20040945A1 PE 2004000120 A PE2004000120 A PE 2004000120A PE 2004000120 A PE2004000120 A PE 2004000120A PE 20040945 A1 PE20040945 A1 PE 20040945A1
Authority
PE
Peru
Prior art keywords
fluoro
phenyl
dimetoxy
chloro
benzyl
Prior art date
Application number
PE2004000120A
Other languages
English (en)
Inventor
Simon Schneider
Klaus Irenaus Steiner
Roy Thomas Winters
Thomas Elliott Jacks
Hubert Gangolf Klemens Barth
Ronald Joseph Heemstra
Nicole Marcia Horne
Bridges Alexander James
Dennis Joseph Mcnamara
Robert Craig Hughes
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20040945A1 publication Critical patent/PE20040945A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE ELABORACION DE QUINAZOLINAS SUBSTITUIDAS DE FORMULA I, ENTRE OTRAS, INCLUYENDO SU SAL, ESTER, AMIDA DONDE R1, R2 Y R3 SON H, HALOGENO, NO2, CN, CF3, ENTRE OTROS; R4 Y R6 SON H, HIDROXI, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; R5 ES FENILO, PIRIDILO, FURILO, TIAZOLILO, ENTRE OTROS; Z ES H, HALOGENO, C1-C6, CICLOALQUILO C3-C8, ENTRE OTROS, CON LA CONDICION QUE CUANDO Z ES MONOVALENTE, R5 ESTA AUSENTE. ESTE METODO COMPRENDE ELIMINAR EL GRUPO PROTECTOR G DE UN COMPUESTO DE FORMULA 10 PARA DAR UN COMPUESTO DE FORMULA 1. SON COMPUESTOS PREFERIDOS: (3-CLORO-4-FLUORO-FENIL)-(3,4-DIMETOXI-BENCIL)-(7-FLUORO-6-NITROQUINAZOLIN-4-IL)-AMINA; (3-CLORO-4-FLUORO-FENIL)-(3,4-DIMETOXI-BENCIL)-[7-(3-MORFOLIN-4-IL-PROPOXI)-6-NITROQUINAZOLIN-4-IL]-AMINA; N4-(3-CLORO-4-FLUORO-FENIL)-N4-(3,4-DIMETOXI-BENCIL)-7-(3-MORFOLIN-4-IL-PROPOXI)-QUINAZOLIN-4,6-DIAMINA; ENTRE OTROS. ESTOS COMPUESTOS SON INHIBIDORES IRREVERSIBLES DE TIROSINA QUINASA Y SON UTILES PARA TRATAR CANCER, RESTENOSIS, ATEROESCLEROSIS, ENDOMETRIOSIS Y PSORIASIS
PE2004000120A 2003-02-05 2004-02-02 Preparacion de quinazolinas substituidas PE20040945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44509503P 2003-02-05 2003-02-05

Publications (1)

Publication Number Publication Date
PE20040945A1 true PE20040945A1 (es) 2004-12-14

Family

ID=32850969

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000120A PE20040945A1 (es) 2003-02-05 2004-02-02 Preparacion de quinazolinas substituidas

Country Status (18)

Country Link
US (1) US20040158065A1 (es)
EP (1) EP1618095A2 (es)
JP (1) JP2006517959A (es)
KR (1) KR20050095916A (es)
CN (1) CN1745073A (es)
AR (1) AR043027A1 (es)
AU (1) AU2004209452A1 (es)
BR (1) BRPI0407249A (es)
CA (1) CA2514933A1 (es)
MX (1) MXPA05007831A (es)
NL (3) NL1025414C2 (es)
PA (1) PA8595201A1 (es)
PE (1) PE20040945A1 (es)
PL (1) PL378576A1 (es)
RU (1) RU2005122322A (es)
TW (1) TW200420544A (es)
UY (1) UY28177A1 (es)
WO (1) WO2004069791A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287010B6 (sk) * 1999-06-21 2009-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyklické heterocyklické zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
WO2005107758A1 (en) * 2004-05-06 2005-11-17 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100832593B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
CA2833852C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
JP2010503717A (ja) * 2006-09-18 2010-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ変異を有する腫瘍を治療するための方法
EP2190287B1 (en) 2007-09-10 2014-10-29 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
JP2011510079A (ja) * 2008-01-22 2011-03-31 コンサート ファーマシューティカルズ インコーポレイテッド ゲフィチニブ誘導体
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
US20100185419A1 (en) * 2008-09-05 2010-07-22 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
WO2013013640A1 (zh) * 2011-07-27 2013-01-31 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
EP2766356B1 (en) * 2011-10-12 2018-08-01 Teligene Ltd. Quinazoline derivatives as kinases inhibitors and methods of use thereof
WO2013166952A1 (en) 2012-05-07 2013-11-14 Teligene Ltd Substituted aminoquinazolines useful as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
CN103242244B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 一种卡奈替尼的制备方法
EP2999702A4 (en) 2013-05-21 2017-01-11 Jiangsu Medolution Ltd. Substituted pyrazolopyrimidines as kinases inhibitors
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
KR102355955B1 (ko) * 2016-09-23 2022-01-25 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
BR112021005513A2 (pt) 2018-09-25 2021-06-22 Black Diamond Therapeutics, Inc. derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
KR20210136033A (ko) * 2019-03-07 2021-11-16 비온테크 에스이 치환된 이미다조퀴놀린의 제조 방법
CA3150701A1 (en) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
JP2024515204A (ja) * 2021-04-22 2024-04-05 ボロノイ インコーポレイテッド ヘテロアリール誘導体化合物およびその用途
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL190489B1 (pl) * 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
US6664390B2 (en) * 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
PA8595201A1 (es) 2004-09-16
JP2006517959A (ja) 2006-08-03
NL1029762C2 (nl) 2006-03-06
CA2514933A1 (en) 2004-08-19
TW200420544A (en) 2004-10-16
RU2005122322A (ru) 2006-03-10
NL1025414A1 (nl) 2004-08-06
MXPA05007831A (es) 2005-10-18
PL378576A1 (pl) 2006-05-02
WO2004069791A2 (en) 2004-08-19
NL1029763A1 (nl) 2005-10-13
AR043027A1 (es) 2005-07-13
NL1029763C2 (nl) 2006-03-06
US20040158065A1 (en) 2004-08-12
WO2004069791A3 (en) 2004-12-16
BRPI0407249A (pt) 2006-01-31
NL1029762A1 (nl) 2005-10-13
UY28177A1 (es) 2004-09-30
EP1618095A2 (en) 2006-01-25
NL1025414C2 (nl) 2005-11-01
KR20050095916A (ko) 2005-10-04
CN1745073A (zh) 2006-03-08
AU2004209452A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
PE20040945A1 (es) Preparacion de quinazolinas substituidas
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
ES2528451T3 (es) Inhibidores de esfingosina cinasa
PE20241356A1 (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer
PE20070527A1 (es) Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20121312A1 (es) Metodo para preparar compuestos macrociclicos inhibidores de serina proteasas de hepatitis c
CO5640090A2 (es) Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
HUP0301236A2 (hu) Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
PE20030975A1 (es) 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20050664A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
CO5580828A2 (es) 3-cianoquinolinas como inhibidores de quinasa egf-r y her2
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PA8676301A1 (es) Metodos para sintetizar derivados de 6-alquilaminoquinolina
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
AR079495A1 (es) Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a

Legal Events

Date Code Title Description
FC Refusal